Soluble HER-2 in patients with head and neck squamous cell carcinoma

Iranian Journal of Otorhinolaryngology

Volumn 25, Issue 72, 2013, Pages 161-167

  Khademi, Bijan ^a   Khademi, Behzad ^b   Ghaderi, Abbas ^a   Hosseini, Seyd Fakhroddin ^a   Niknejad, Nika ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

EGFR; HER 2; HNSCC; Tmor marker

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SMOKING HABIT; TUMOR INVASION; TUMOR VOLUME;

EID: 84903934867     PISSN: 22517251     EISSN: 2251726X     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Abukhedir AM, Park BH. P21 and P27 roles in carcinogenesis and drug resistance. Expert Rev Mol Med 2008; 10:e19.
2. Agra IM, Carvalho AL, Pinto CA, Martins EP, Filho JG, Soares FA et al. Biological markers and prognostic in recurrent oral cancer after salvage surgery. Arch Otolaryngol Head Neck Surg 2008; 134: 743-9.
3. Arcasoy MO, Amin K, Chou SC, Haroon ZA Varia M, Raleigh JA. Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. Clin Cancer Res 2005; 11:20-27.
4. Arora S, Kaur J, Sharma C, Mathur M, Bahadur S, Shukla NK et al. Sromelysin 3, Ets-1, and vascular endothelial growth factor expression in oral precancerous and cancerous lesions: correlation with micro vessel density, progression and prognosis. Clin Cancer Res 2005; 11: 2272-84.
5. Barnett SF, Bilodeau MT, Lindsley CW. The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation. Curr Top Med Chem 2005; 5: 109-25.
6. Barnett SF, De Fromentel CC, Puisieux A, Galmarini CM. P53 as a target for anti-cancer drug development. Crit Rev Oncol Hematol 2006; 58: 109-25.
7. Brennan PA, Mackenzie N, Ouinetro M. Hypoxia-inducible factor 1-alpha in oral cancer. J Oral Pathol Med 2005; 34: 385-9.
8. Bukkwinkel J, Baron-Luhr B, Ludemann A, Wohlenberg C, Gerdes J, Scholzen T. Ki- 67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells. J Cell Physiol 2006; 206: 624-35.
9. Camisasca DR, Honorato J, Bernardo V, Da Silva LE, Lorenco SDE Q. Expression of Bcl-2 family proteins and associated clinicopathologic factors predict survival outcome in patients with oral squamous cell carcinoma. Oral Oncol 2009; 45: 225-33.
10. Campell TN, Robbins SM. The Eph receptor/ephrin system: an emerging player in the invasion game. Curr Issues Mol Biol 2008; 10: 61-6.
11. Chari NS, Pinaire NL, Thorpe L, Meidros LJ, Routbort MJ, McDonell TJ. The p53 tumor suppression network in cancer and the therapeutic modulation of cell death. Apoptosis 2009; 14:336-47.
12. Chien CY, Su CY, Hwang CF, Chuang HC, Chen CM, Huang CC. High expression of CD105 and VEGF in early oral cancer predict potential cervical metastasis. J Surg Oncol 2006; 94: 413-17.
13. Choi SW, Kim JY, Park Jycha IH, Kim, Lee S. expression of carbonic anhydrase IX is associated with post-operative recurrence and poor prognostic in surgically treated oral squamous cell carcinoma. Hun Pathol 2008; 39: 1317-22.
14. Chuang HC, Su CY, Huang HY, Chien CY, Chen CM, Huang CC. High expression of CD105 as a prognostic predictor of early tongue cancer. Laryngoscope 2006; 116: 1175-79.
15. Curran D, Giralt J, Harari Ang KK, Cohen RB, Kies MS, Jassem J. Quality of life in headand neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 2007; 25: 2152-55.
16. De Vicente JC, Frenso MF, Villalain L, Vega JA, Hernandez Vallejo G. Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma. Oral Oncol 2005; 41: 283-93.
17. Jacobs TW, Gown AM, Yazji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-Approved scoring system. J Clin Oncol 1999; 17: 1983-7.
18. Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 2003; 95: 851-67.
19. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Eng J Med 2008;358: 1160-74.
20. Cavalot A, Martone T, Roggero N, Brondino G, Pagano M, Cortesina G. Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas. Head Neck 2007; 29: 655-64.
21. Wei Q, Sheng L, Shui Y, Hu Q, Nordgren H, Carlsson J. EGFR, HER2, and HER3 expression in laryngeal and primary tumors and corresponding metastases. Ann Surg Oncol 2008; 15: 1193-201.
22. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al: Studies of HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
23. Takehana T, Kunitomo K, Kitahara F, Iizuka H, Matsumoto Y, Fujino MA., Status of c-erb-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immune-sorbent assay. Int J Cancer 2002; 98: 833-37.
24. Osako T, Miyahara M, Uchino S, Kitano S, Kobayashi M. Immunohistochemica lstudy of c-erb-2 protein in colorectal cancer and the correlation with patient survival. Oncology 1998; 55: 548-55.
25. D'Emilla J, Bulovas K, D'Ercole K, Wolf B, Steele G Jr, Summerhayes IC. Expression of the c-erb-2 gene product (p185) at different stages of neoplastic progression in the colon. Oncogene 1989; 4: 1233-39.
26. Takikita M, Xie R, Chung JY, Cho H, Ylaya K, Hong SNM et al. Membranous expression of HER-3 is associated with a decreased survival in head and neck squamous cell carcinoma. J Trans Med 2011; 9: 126.
27. Field JK, Spandidos DA, Yiagnisis M, Gosney JR, Papadimitriou K, Stell PM. C-erb-2 expression in squamous cell carcinoma of head and neck. AnticancerRes 1992; 12: 613-19.
28. Craven JM, Pavelik ZP, Strarnbrook PJ, Pavelic L, Gapany M, Kelley DJ et al. Expression of c-erb-2 gene in human head and neck carcinoma. Anticancer Res 1992; 12: 2273-76.
29. Hoffman TK, Ballo H, Braunstien S, Van Lierop A, Wagerman M, Bier H. Serum level and tissue expression of c-erb-1 and c-erb-2 proto-oncogene products in patients with squamous cell carcinoma of the head and neck. Oral Oncol 2001; 37:50-6.